We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Paladin Labs Inc. and Endo Ventures Limited, subsidiaries of Endo International plc (NASDAQ: ENDP), today announced Health Canada's approval of Envarsus PA™(tacrolimus prolonged-release tablets) for the prophylaxis of organ rejection in kidney or liver t